Quantum Biopharma (QNTM) Liabilities and Shareholders Equity (2021 - 2025)
Quantum Biopharma's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $11.2 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 34.8% to $11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.5 million, a 7.96% increase, with the full-year FY2025 number at $11.2 million, down 34.8% from a year prior.
- Liabilities and Shareholders Equity hit $11.2 million in Q4 2025 for Quantum Biopharma, down from $14.2 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for QNTM hit a ceiling of $63.0 million in Q4 2021 and a floor of $11.2 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $22.6 million across 5 years, with a median of $16.2 million in 2024.
- Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 54.51% in 2023 and later grew 0.33% in 2025.
- Tracing QNTM's Liabilities and Shareholders Equity over 5 years: stood at $63.0 million in 2021, then crashed by 38.99% to $38.4 million in 2022, then plummeted by 54.51% to $17.5 million in 2023, then dropped by 2.03% to $17.1 million in 2024, then plummeted by 34.8% to $11.2 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for QNTM at $11.2 million in Q4 2025, $14.2 million in Q3 2025, and $15.3 million in Q2 2025.